Positions

Overview

  • A graduate of Boston University in Boston, Massachusetts, Dr. Davis completed medical school at the University of Alabama School of Medicine (UASOM), where he also served his internship, residency, and the ABIM academic subspecialty research fellowship clinical investigator pathway in Hematology/Oncology. He is Professor of Medicine, Microbiology, and Biochemistry and Molecular Genetics in the division of Hematology/Oncology. He is board certified in Hematology.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Evolution of Fc Receptor-Like Scavenger in Mammals.  Frontiers in Immunology.  11. 2021
    2021 Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency 2021
    2020 Roles for the FCRL6 Immunoreceptor in Tumor Immunology.  Frontiers in Immunology.  11. 2020
    2020 Fc Receptor-Like 6 (FCRL6) Discloses Progenitor B Cell Heterogeneity That Correlates With Pre-BCR Dependent and Independent Pathways of Natural Antibody Selection.  Frontiers in Immunology.  11. 2020
    2020 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology 2020
    2019 Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.  Blood Cancer Journal.  9. 2019
    2019 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019 2019
    2018 Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.  JCI insight.  3. 2018
    2018 Plasmodium-specific atypical memory B cells are short-lived activated B cells.  eLife.  7. 2018
    2018 Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education.  Translational Behavioral Medicine.  8:175-182. 2018
    2017 Hairy cell Leukemia, Version 2.2018: Clinical practice guidelines in oncology 2017
    2017 Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia..  Clinical Case Reports.  5:899-901. 2017
    2015 FCRL regulation in innate-like B cells.  Annals of the New York Academy of Sciences.  1362:110-116. 2015
    2015 Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia 2015
    2014 Emerging roles for the FCRL family members in lymphocyte biology and disease.  Current Topics in Microbiology and Immunology.  382:29-50. 2014
    2013 FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation.  European Journal of Immunology.  43:2980-2992. 2013
    2013 FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling 2013
    2011 FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling.  Blood.  118:6332-6341. 2011
    2011 Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia.  Blood.  118:4902-4909. 2011
    2011 Unraveling the molecular pathogenesis of chronic lymphocytic leukemia: Dissecting a microRNA regulatory network 2011
    2011 FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA.  International Immunology.  23:43-53. 2011
    2010 FcR-like 2 inhibition of B cell receptor-mediated activation of B cells.  Journal of Immunology.  185:7405-7412. 2010
    2010 Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin.  Journal of Immunology.  185:28-32. 2010
    2010 Cutting edge: FcR-like 6 is an MHC class II receptor.  Journal of Immunology.  185:23-27. 2010
    2010 Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.  Journal of Clinical Oncology.  28:1749-1755. 2010
    2010 Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098).  Clinical Lymphoma, Myeloma and Leukemia.  10:157. 2010
    2009 The FCRL3 -169CT promoter single-nucleotide polymorphism, which is associated with systemic lupus erythematosus in a Japanese population, predicts expression of receptor protein on CD19+ B cells.  Arthritis and Rheumatism.  60:3510-3512. 2009
    2009 Tumor Suppression by Phospholipase C-β3 via SHP-1-Mediated Dephosphorylation of Stat5.  Cancer Cell.  16:161-171. 2009
    2008 FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia.  European Journal of Immunology.  38:3159-3166. 2008
    2008 FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.  Blood.  112:179-187. 2008
    2007 IgEb immune complexes activate macrophages through FcγRIV binding.  Nature Immunology.  8:762-771. 2007
    2007 Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment 2007
    2007 Fc receptor-like molecules.  Annual Review of Immunology.  25:525-560. 2007
    2007 Fc receptor-like proteins (FCRL): immunomodulators of B cell function..  Advances in Experimental Medicine and Biology.  596:155-162. 2007
    2007 A Comparative Study of Diffuse Large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB)..  Blood.  110:4430-4430. 2007
    2007 FCRL2 expression is predictive of IgVH mutation status and clinical progression in chronic lymphocytic leukemia.  Blood.  S110:150a-151a. 2007
    2007 FCRL2 is a Novel Prognostic Marker in B Cell Chronic Lymphocytic Leukemia 2007
    2007 Fc receptor-like proteins (FCRL): Immunomodulators of B cell function.  Advances in Experimental Medicine and Biology.  596:155-162. 2007
    2006 Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells.  Journal of Immunology.  177:6815-6823. 2006
    2006 New nomenclature for Fc receptor-like molecules [1].  Nature Immunology.  7:431-432. 2006
    2005 FcRY, an Fc receptor related gene differentially expressed during B lymphocyte development and activation.  Gene.  363:32-40. 2005
    2005 Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells.  Journal of Experimental Medicine.  202:783-791. 2005
    2005 An extended family of Fc receptor relatives.  European Journal of Immunology.  35:674-680. 2005
    2005 FcRH1: An activation coreceptor on human B cells.  Blood.  105:1121-1126. 2005
    2005 Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B.  Journal of Gastroenterology and Hepatology.  20:433-440. 2005
    2004 Differential B cell expression of mouse Fc receptor homologs.  International Immunology.  16:1343-1353. 2004
    2003 The inhibitory potential of Fc receptor homolog 4 on memory B cells 2003
    2002 Fc receptor homologs: Newest members of a remarkably diverse Fc receptor gene family.  Immunological Reviews.  190:123-136. 2002
    2002 Definition of an Fc receptor-related gene (FcRX) expressed in human and mouse B cells.  International Immunology.  14:1075-1083. 2002
    2002 Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.  Gastroenterology.  123:719-727. 2002
    2002 Fc receptor homologs (FcRH1-5) extend the Fc receptor family.  Current Topics in Microbiology and Immunology.  266:85-112. 2002
    2001 Identification of a family of Fc receptor homologs with preferential B cell expression 2001

    Book

    Year Title Altmetric
    2014 Emerging roles for the FCRL family members in lymphocyte biology and disease.  Ed. 382.  2014

    Chapter

    Year Title Altmetric
    2004 The Development of Human B Lymphocytes.  141-154. 2004

    Research Overview

  • Dr. Davis' laboratory is focused on the cellular and molecular immunobiology of lymphocytes in normal and diseased conditions. He has been broadly trained as a physician-scientist with a background in basic lymphocyte development and receptor biology. As a postdoctoral fellow he co-discovered a multigene family that encodes Fc receptor-like (FCRL) molecules with tyrosine-based regulatory potential that are expressed by subpopulations of lymphocytes in normal and diseased states. Current work involves investigating FCRL members in humans and mice to define their functional roles in normal and aberrant immune conditions. Work by his group and through productive collaborations has provided a better understanding of these receptors in basic immunology as well as in clinically important autoimmune and malignant conditions. Beyond his role as a physician-scientist, he also serves as Director of the UAB Multidisciplinary Molecular Interaction (MMIC) Core Facility which supports the operation of a Biacore T200 instrument. This technology allows for the determination of very sensitive kinetic interactions between macromolecules and/or small drugs using surface plasmon resonance (SPR).

    • Principal Investigator On

  • Evaluation of FCRL1 as Therapeutic Target in B Cell Disorders  awarded by UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER (MEMPHIS) 2021 - 2026
  • Research Collaboration with University of Tennessee Health Science Center FCRL5 Antibody  awarded by UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER (MEMPHIS) 2020 - 2023
  • Targeting Adaptive Resistance to Checkpoint Blockade in Solid Tumors  awarded by V FOUNDATION FOR CANCER RESEARCH 2019 - 2022
  • FCRL Regulation in B cell Malignancy  awarded by American Society of Hematology ^ 2020 - 2022
  • Biological significance of receptor ligand interactions in human FCRL6 and HLA class-II molecules  awarded by HEINRICH-PETTE-INSTITUT 2020 - 2021
  • Roles of FCRL Molecules in Innate Immunity  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2015 - 2020
  • Targeting FCRL1 for Treatment in CLL  awarded by Leukemia and Lymphoma Society 2016 - 2020
  • Cellular and Biologic Origins in CLL  awarded by National Cancer Institute/NIH/DHHS 2014 - 2015
  • Biological Role of FCRL Molecules in SLE Pathogenesis  awarded by LUPUS RESEARCH ALLIANCE 2012 - 2015
  • Modeling FCRL6 Regulation and Function in Transgenic Mice  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2012 - 2015
  • Validating a Novel Biomarker of Clinical Progression and Survival in CLL  awarded by National Cancer Institute/NIH/DHHS 2011 - 2015
  • Roles of FCRL Molecules in Innate Immunity  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2015
  • Functional Role of Fc Receptor Homologs on B Lineage Cells  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2007 - 2013
  • Defining the Functional Role of FcRH1 in B Cells  awarded by American Cancer Society, Inc. 2008 - 2012
  • 2010 ASH Trainee Research Award  awarded by American Society of Hematology ^ 2010 - 2011
  • Biological Definition of FCRL Molecules in Malignancy  awarded by National Cancer Institute/NIH/DHHS 2008 - 2011
  • Exploring the Biological Role of Fc Receptor Homologs  awarded by Cancer Research Institute, Inc. 2006 - 2011
  • Potential Role of FCRL2 as a Surrogate Marker of IgVH Mutation in CLL  awarded by CLL GLOBAL RESEARCH FOUNDATION 2007 - 2011
  • UAB Shared Biacore T100 Biosensor  awarded by National Center for Research Resources/NIH/DHHS 2010 - 2011

    • Investigator On

    Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 1997
  • Bachelor of Science or Mathematics in Biology, Boston University 1994
  • UAB Hospital, Internship 1998
  • UAB Hospital, Residency 1999
  • UAB Hospital, Postdoctoral Fellowship 2003

    • Full Name

  • Randall Davis